3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
23
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Biopsy
7
dabrafenib
6
Surveys and Questionnaires
6
Dacarbazine
6
trametinib
5
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Blood Specimen Collection
5
Aminolevulinic Acid
5
sonidegib
4
encorafenib
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Educational Status
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Dermatologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled